Melblez Kit (melphalan hepatic delivery system) Trials

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Melblez Kit (melphalan hepatic delivery system) / Delcath

2015-000417-44: A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with cancer of the eye that has spread to the liver.

Ongoing

240

Europe

Melphalan, Powder and solvent for solution for infusion, Melphalan Hydrochloride for Injection

Delcath Systems, Inc, Delcath Systems, Ltd, DELCATH SYSTEMS, INCORPORATIONS, Delcath Systems, Inc

Hepatic-Dominant Ocular Melanoma, Cancer of the eye that has spread to the liver, Diseases [C] - Cancer [C04]

FOCUS, NCT02678572 / 2015-000417-44: Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Completed

102

Europe, US

Melphalan/HDS, Alkeran

Delcath Systems Inc., IQVIA Biotech

Melanoma, Ocular

05/23

08/23

NCT05022901: An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Active, not recruiting

Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS), percutaneous hepatic perfusion, PHP, HEPZATO

Delcath Systems Inc.

Metastatic Ocular Melanoma, Metastatic Uveal Melanoma

03/24

NCT03086993 / 2016-003812-10: Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Active, not recruiting

2/3

295

Melphalan/HDS, Melphalan/PHP, Cisplatin and Gemcitabine, Cis/Gem

Delcath Systems Inc.

Bile Duct Cancer, Intrahepatic Cholangiocarcinoma

01/23

05/23

NCT06607458: Evaluation of the Safety and Efficacy of Treatment W/High Dose Melphalan Given Directly Into the Liver Followed by Treatment W/approved Cancer Treatment or Approved Cancer Treatment Alone in Patients W/ Metastatic Colorectal Cancer W/liver Dominant Disease

Not yet recruiting

Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Melphalan, HDS, Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil, Melphalan/HDS, Trifluridine-tipiracil plus Bevacizumab Alone, Bevacizumab

Delcath Systems Inc.

Refractory Metastatic Colorectal Cancer

12/26

10/27



	Diseases Companies Products Productz Mechanisms of Action Sites